The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Genetic Modifiers of Liver Disease in Cystic Fibrosis
Open accessAbstract
CONTEXT: A subset (approximately 3%-5%) of patients with cystic fibrosis (CF) develops severe liver disease with portal hypertension. OBJECTIVE: To assess whether any of 9 polymorphisms in 5 candidate genes (alpha(1)-antitrypsin or alpha(1)-antiprotease [SERPINA1], angiotensin-converting enzyme [ACE], glutathione S-transferase [GSTP1], mannose-binding lectin 2 [MBL2], and transforming growth factor beta1 [TGFB1]) are associated with severe liver disease in patients with CF. DESIGN, SETTING, AND PARTICIPANTS: Two-stage case-control study enrolling patients with CF and severe liver disease with portal hypertension (CFLD) from 63 CF centers in the United States as well as 32 in Canada and 18 outside of North America, with the University of North Carolina at Chapel Hill as the coordinating site. In the initial study, 124 patients with CFLD (enrolled January 1999-December 2004) and 843 control patients without CFLD were studied by genotyping 9 polymorphisms in 5 genes previously studied as modifiers of liver disease in CF. In the second stage, the SERPINA1 Z allele and TGFB1 codon 10 genotype were tested in an additional 136 patients with CFLD (enrolled January 2005-February 2007) and 1088 with no CFLD. MAIN OUTCOME MEASURES: Differences in distribution of genotypes in patients with CFLD vs patients without CFLD. RESULTS: The initial study showed CFLD to be associated with the SERPINA1 Z allele (odds ratio [OR], 4.72; 95% confidence interval [CI], 2.31-9.61; P = 3.3 x 10(-6)) and with TGFB1 codon 10 CC genotype (OR, 1.53; 95% CI, 1.16-2.03; P = 2.8 x 10(-3)). In the replication study, CFLD was associated with the SERPINA1 Z allele (OR, 3.42; 95% CI, 1.54-7.59; P = 1.4 x 10(-3)) but not with TGFB1 codon 10. A combined analysis of the initial and replication studies by logistic regression showed CFLD to be associated with SERPINA1 Z allele (OR, 5.04; 95% CI, 2.88-8.83; P = 1.5 x 10(-8)). CONCLUSIONS: The SERPINA1 Z allele is a risk factor for liver disease in CF. Patients who carry the Z allele are at greater risk (OR, approximately 5) of developing severe liver disease with portal hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Webb, A. K. (2006) · Cited by 4,369
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Tests for Linear Trends in Proportions and Frequencies
Armitage, P. (1955) · Biometrics · doi:10.2307/3001775 · Cited by 2,071
The occurrence of lung cancer in man.
Ml, L. (1953) · PubMed · Cited by 981
Genetic Modifiers of Lung Disease in Cystic Fibrosis
Drumm, M. L., Konstan, M. W., Schluchter, M. D., Handler, A., Pace, R., Zou, F., Zariwala, M., Fargo, D., Xu, A., Dunn, J. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051469 · Cited by 504
Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome
Colombo, C., Battezzati, P. M., Crosignani, A., Morabito, A., Costantini, D., Padoan, R., & Giunta, A. (2002) · Hepatology · doi:10.1002/hep.1840360613 · Cited by 377
Cohn, J. A., Strong, T. V., Picciotto, M. R., Nairn, A. C., Collins, F. S., & Fitz, J. G. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)91085-v · Cited by 357
Tsukada, S., Parsons, C. J., & Rippe, R. A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.014 · Cited by 357
Heritability of Lung Disease Severity in Cystic Fibrosis
Vanscoy, L. L., Blackman, S. M., Collaco, J. M., Bowers, A., Lai, T., Naughton, K., Algire, M., McWilliams, R., Beck, S., Hoover-Fong, J., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200608-1164oc · Cited by 200
Analysis of risk factors for the development of liver disease associated with cystic fibrosis
Colombo, C., Apostolo, M. G., Ferrari, M., Seia, M., Genoni, S., Giunta, A., & Sereni, L. P. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70361-2 · Cited by 189
Liver disease in cystic fibrosis
Colombo, C. (2007) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3282f10a16 · Cited by 173
Lawless, M. W., Greene, C. M., Mulgrew, A., Taggart, C. C., O’Neill, S. J., & McElvaney, N. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5722 · Cited by 172
Increased risk of chronic liver failure in adults with heterozygous α-antitrypsin deficiency
Graziadei, I. W., Joseph, J. J., Wiesner, R. H., Therneau, T. M., Batts, K. P., & Porayko, M. K. (1998) · Hepatology · doi:10.1002/hep.510280421 · Cited by 151
Liver Disease in Cystic Fibrosis
Colombo, C., Russo, M. C., Zazzeron, L., & Romano, G. (2006) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/01.mpg.0000226390.02355.52 · Cited by 150
Complex two-gene modulation of lung disease severity in children with cystic fibrosis
Dorfman, R., Sandford, A. J., Taylor, C. A., Huang, B., Frangolias, D. D., Wang, Y., Sang, R., Pereira, L., Sun, L., Berthiaume, Y., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33754 · Cited by 146
Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension
Debray, D., Lykavieris, P., Gauthier, F., Dousset, B. E., Sardet, A., Munck, À., Laselve, H., & Bernard, O. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80166-4 · Cited by 142
Mekus, F., Ballmann, M., Bronsveld, I., Bijman, J., Veeze, H. J., & Tümmler, B. (2000) · Twin Research · doi:10.1375/136905200320565256 · Cited by 130
Cholangiocyte Biology and Cystic Fibrosis Liver Disease
Feranchak, A. P., & Sokol, R. J. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-19030 · Cited by 127
Clinical and Genetic Risk Factors for Cystic Fibrosis-related Liver Disease
Wilschanski, M. A., Rivlin, J., Cohen, S., Augarten, A., Blau, H., Aviram, M., Bentur, L., Springer, C., Vila, Y., Branski, D., et al. (1999) · PEDIATRICS · doi:10.1542/peds.103.1.52 · Cited by 124
Pathogenesis of Chronic Liver Injury and Hepatocellular Carcinoma in Alpha-1-Antitrypsin Deficiency
Perlmutter, D. H. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000228350.61496.90 · Cited by 103
Chronic liver disease in heterozygous α1-antitrypsin deficiency PiZ
Fischer, H., Ortiz-Pallardó, M. E., Ko, Y. D., Esch, C., & Zhou, H. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80119-1 · Cited by 86
Kinnman, N., Lindblad, A., Housset, C., Buentke, E., Scheynius, A., Strandvik, B., & Hultcrantz, R. W. (2000) · Hepatology · doi:10.1053/jhep.2000.9111 · Cited by 84
Bremer, L. A., Blackman, S. M., Vanscoy, L. L., McDougal, K. E., Bowers, A., Naughton, K., Cutler, D. J., & Cutting, G. R. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn123 · Cited by 81
Cystic fibrosis–associated liver disease: a population-based study
Corbett, K., Kelleher, S., Rowland, M., Daly, L., Drumm, B., Canny, G. J., Greally, P., Hayes, R. M., & Bourke, B. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.05.051 · Cited by 79
Regev, A., Guaqueta, C. B., Molina, E. G., Conrad, A. J., Mishra, V. S., Brantly, M., Torres, M., de Medina, M. D., Tzakis, A. G., & Schiff, E. R. (2006) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/01.mpg.0000226387.56612.1e · Cited by 78
Arkwright, P. D., Pravica, V., Geraghty, P. J., Super, M., Webb, A. K., Schwarz, M. J., & Hutchinson, I. V. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200204-364oc · Cited by 67
Alpha-1 antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis
Mencin, A. M., Seki, E., Osawa, Y., Kodama, Y., Minicis, S. D., Knowles, M. R., & Brenner, D. A. (2007) · Hepatology · doi:10.1002/hep.21832 · Cited by 59
α1-Antitrypsin Deficiency Alleles in Cystic Fibrosis Lung Disease
Frangolias, D. D., Ruan, J., Wilcox, P. J., Davidson, A. G. F., Wong, L. T. K., Berthiaume, Y., Hennessey, R., Freitag, A. P., Pedder, L., Corey, M. L., et al. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2002-0271oc · Cited by 51
RE: “SIMPLE ESTIMATION OF POPULATION ATTRIBUTABLE RISK FROM CASE-CONTROL STUDIES”
Levin, M. L., & Bertell, R. (1978) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112590 · Cited by 44
Liver disease in cystic fibrosis
Colombo, C., Poala, S. B., Motta, V., & Zazzeron, L. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6393-0_12 · Cited by 26
Yang, Q., Khoury, M. J., Friedman, J. M., & Flanders, W. D. (2003) · Epidemiology · doi:10.1097/01.ede.0000040256.22618.12 · Cited by 21
Gene Modifiers in Pediatrics: Application to Cystic Fibrosis
Sontag, M. K., & Accurso, F. J. (2004) · Advances in Pediatrics · doi:10.1016/s0065-3101(23)00034-8 · Cited by 15
Cited by
Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,805
Cystic fibrosis genetics: from molecular understanding to clinical application
Cutting, G. R. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3849 · Cited by 965
Alpha 1 -Antitrypsin Deficiency
Strnad, P., McElvaney, N. G., & Lomas, D. A. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1910234 · Cited by 515
Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease
Debray, D., Kelly, D., Houwen, R., Strandvik, B., & Colombo, C. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60006-4 · Cited by 432
Guerriero, C. J., & Brodsky, J. L. (2012) · Physiological Reviews · doi:10.1152/physrev.00027.2011 · Cited by 418
Metadata
- Authors
- Bartlett, J. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-09-09
- Volume
- 302
- Issue
- 10
- Pages
- 1076
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120478186
- Cited by
- 308
- References
- 36
- FWCI
- 16.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.